Fig. 3
Cryopreserved tolDC-MOG treatment suppresses EAE progression. Clinical follow-up of mice treated with 1 × 106 viable frozen tolDC-MOG (f-tolDC-MOG, n = 8) or PBS (vehicle, n = 8) on days +15 pi, +19 pi and +23 pi (a). Arrows indicate days of treatment administration. Error bars correspond to SEM. Representation of individual clinical score of the initial day of treatment (day 15 pi) and the corresponding mean clinical score during the treatment period (from 16 pi to 30 pi) from mice treated with f-tolDC-MOG (n = 8) (b) or PBS (vehicle, n = 8) (c). The mean clinical score during the treatment for each mouse was calculated as the sum of daily scores from day 16 pi to 30 pi divided by 15 (number of follow-up days after treatment)